About 90% of sporadic BCC patients have an identifiable loss-of-function mutation in at least one allele of PTCH1, 30% have biallelic inactivation, and the remaining 10% have activating gain-of-function mutations in SMO. This evidence concerns the gene SMO and skin basal cell carcinoma.